3rd-qtr results from Eli Lilly miss forecasts

25 October 2016

US pharma major Eli Lilly (NYSE: LLY) reported third-quarter 2016 financial results that disappointed Wall Street and saw the company’s share fall 1.5% to $76.40 in pre-market trading, although the stock levelled off to just a 0.26% fall just before close of trading.

Revenues for the three months were up 4.7% to $5.19 billion but fell short of the $5.35 billion expected by four analysts surveyed by Zacks Equity Research, as sales were hit by a disappointing performance of its Humalog insulin and animal health products

Lilly’s earnings were $778 million in the third quarter, down 1.5%. Adjusted results came in at $0.88 per share. On average, analysts expected earnings of $0.96 per share, according to Zacks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical